5 results about "Hypromellose acetate succinate" patented technology

The present invention provides a solid dispersion comprising lurasidone or a pharmaceutically acceptable salt thereof and a carrier. The carrier material includes polyvinyl acetate phthalate (PVAP), polyvinyl alcohol (PVA), cellulose acetate phthalate (CAP), mesoporous silica, hydroxypropyl methylcellulose (HPMC), polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, acrylic resin, hydroxypropyl cellulose (HPC), povidone, copovidone, ethylcellulose, polyoxyethylene glycol, hypromellose acetate succinate (HPMCAS), hypromellose phthalate (HPMCP), or a combination thereof.

This invention discloses a pharmaceutical composition comprising a heterocyclic compound, the pharmaceutical composition comprising the following components: (a) a compound of formula (I); and (b) hydroxypropyl methylcellulose acetate succinate or copovidone; wherein components (a) and (b) are mixed and subjected to thermal melt extrusion, wherein the weight ratio of component (b) to component (a) is 0.4 to 0.8. The pharmaceutical composition of this invention exhibits stable storage over extended periods under conditions of room temperature and high relative humidity, and demonstrates significantly improved dissolution performance.

The application belongs to the technical field of pharmaceutical preparations and relates to a preparation method of apaziquone tablets. The preparation method comprises the following steps: (1) preparing a solution containing apaziquone and hydroxypropyl methyl cellulose acetate succinate; (2) using part of microcrystalline cellulose as a substrate, one-step granulation is performed on the solution to obtain granules; (3) the granules are crushed to obtain fine granules; and (4) the fine granules, the remaining microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate are mixed and then compressed into a tablet core. According to the preparation method, on the basis of a selected prescription, a spray drying device or a hot melt extrusion device does not need to be introduced, dry granulation or drug particle size control does not need to be performed, one-step granulation is performed on a fluidized bed, the process is highly accessible, the cost is lower, and the product has a dissolution curve basically consistent with that of an original drug.

The application relates to the technical field of pharmaceutical auxiliaries, and particularly discloses an enteric plant capsule and a preparation method thereof. The enteric plant capsule comprises a film-forming material, an enteric coating mixed solution and an ethyl cellulose aqueous solution; the enteric coating mixed solution comprises 50-120 parts of hydroxypropyl methyl cellulose acetate succinate, 50-120 parts of hydroxypropyl methyl cellulose phthalate and 200-500 parts of a sodium hydroxide aqueous solution; the mass concentration of the sodium hydroxide aqueous solution is 0.04-0.4 mg / L; and the preparation method is as follows: the prepared enteric coating mixed solution is added into the prepared film-forming material, vacuum extraction is carried out at 60-70 DEG C and a vacuum degree of 0.065-0.092 MPa for 15-30 min, the prepared ethyl cellulose aqueous solution is added, and a glue solution is obtained; the glue solution is subjected to glue melting and glue dipping forming, and then drying, so that the enteric plant capsule with low water content, stable properties and high storage stability is obtained.

There is disclosed a dispersion of amorphous uridine triacetate in Hypromellose Acetate Succinate-MG and optionally also Copovidone. The amorphous dispersion compositions allow high loading of uridine. They also have good stability and oral bioavailability. They can be used to deliver exogenous uridine to a mammalian subject in need thereof, for example a subject who has an energy failure disorder or certain other conditions.